Role of Plasma Neutrophil Gelatinase Associated Lipocalin as a New Biomarker

1. Fodor R, Grigorescu B, veres M, et al. Plasma neutrophil Gelatinase Associated Lipocalin (NGAL) - Early Biomarker for Acute Kidney Injury in Critically Ill Patients. J Crit Care Med. 2015;4:154-61.Search in Google Scholar

2. Fuernau G, Poenisch C, Eitel I, et al. Prognostic impact of established and novel renal function biomarkers in myocardial infarction with cardiogenic shock: A biomarker substudy of the IABP-SHOCK II-trial. Int J Cardiol. 2015;191:159-66.10.1016/j.ijcard.2015.04.24225965624Search in Google Scholar

3. Torregrosa I, Montoliu C, Urios A, et al. Urinary KIM-1, NGAL and L-FABP for the diagnosis of AKI in patients with acute coronary syndrome or heart failure undergoing coronary angiography. Heart Vessels. 2015;30:703-11.10.1007/s00380-014-0538-z24989970Search in Google Scholar

4. Lindberg S, Pedersen SH, Mogelvang R, et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with STsegment elevation myocardial infarction treated with primary percutaneous coronaryintervention. J Am Coll Cardiol. 2012;60:339-45.10.1016/j.jacc.2012.04.01722813613Search in Google Scholar

5. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol. 2006;26:136-42. 10.1161/01.ATV.0000193567.88685.f416254208Search in Google Scholar